In: Accounting
CVRX Ltd., one of the world’s largest biotechnology companies, invests considerable amounts in research and development each year. In the most recent fiscal year (2020), the R&D expense was $500 million, the net income was $1,000 million, and the book value of equity was $8,000 million. The R&D expenses for the prior 3 years are as follows: $1,200 million (2019), $900 million (2018), and $600 million (2017).
Amortization in 2020 = ……………………
Amortization in 2019 = ……………………
Amortization in 2018 = ……………………
Amortization in 2017 = …………………....
Value of Research Asset in 2020 = ……………………
Net Income (before capitalisation) = ……………………
Net Income (after capitalisation) = ……………………
BVE (before capitalisation) = ……………………
BVE (after capitalisation) =……………………
ROE (before capitalisation) = ……………………
ROE (after capitalisation) =……………………
a) Free Cash Flows are unaffected by the capitalization of the Expenses.
a)While the free cash flow is unaffected by capitalization of these expenses, the reinvestment rate will change. In general, if earnings and reinvestment both increase as a consequence of the capitalization of R&D or advertising expenses, the reinvestment rate will increase
Since both earnings and capital invested are both affected by capitalization, the net effects on return on equity and capital are unpredictable. If the return on equity (capital) increases after the recapitalization, it can be considered a rough indicator that the returns earned by the firm on its R&D or advertising investments is greater than its returns on traditional investments
a)vin millions
Amortization in 2020 = 867
Amortization in 2019 = 900
Amortization in 2018 = 500
Amortization in 2017 = 200
Working
600 | 900 | 1200 | 500 | ||
2017 | 200 | 200 | |||
2018 | 200 | 300 | 500 | ||
2019 | 200 | 300 | 400 | 900 | |
2020 | 300 | 400 | 167 | 867 |
a) Value of research asset in 2020
Total R& D = 3200
Amortization = 2467
Balance (i-ii) = 733
a) WACC of CRVX Ltd. decreased to 10% after capitalising the R&D expenses, its not recommended for the company to invest on R&D .